Akebia Therapeutics, Inc. (AKBA) Financials

AKBA Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 362.5 million 335.1 million
Dec. 31, 2025 376.6 million 344.0 million
Sept. 30, 2025 364.2 million 322.6 million
June 30, 2025 345.6 million 316.4 million

AKBA Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -21.2 million 3.7 million
Dec. 31, 2025 31.0 million 3.2 million
Sept. 30, 2025 28.0 million 3.2 million
June 30, 2025 22.2 million 2.7 million

AKBA Net Income

No data available :(

AKBA Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 162.6 million - -
Dec. 31, 2025 184.8 million 48.3 million 3.5 million
Sept. 30, 2025 166.4 million 47.6 million 4.9 million
June 30, 2025 137.3 million 47.1 million 6.3 million

AKBA Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 267.0 million
Dec. 31, 2025 265.4 million
Sept. 30, 2025 274.4 million
June 30, 2025 271.1 million

AKBA Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 62000 14.8 million 30.4 million -
Dec. 31, 2025 162000 26.6 million 26.1 million -
Sept. 30, 2025 77000 14.6 million 30.0 million -
June 30, 2025 126000 11.0 million 26.6 million -

AKBA Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 53.5 million 12.6 million
Dec. 31, 2025 57.6 million 12.2 million
Sept. 30, 2025 58.8 million 9.7 million
June 30, 2025 62.5 million 9.9 million

AKBA Revenue by Segment
Graph available only for paid members. Upgrade to see it.

AKBA

Price: $1.30

52 week price:
0.82
4.08

Earnings Per Share: -0.08 USD

Exchange: NCM

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Country: United States

Volume: 1.3 million

Ebitda: -24.0 million

Market Capitalization: 332.6 million

Links: